A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy

AU-011/bel-sar Phase 2 data showed strong tumor control (~80% freedom from progression at 15 months) and visual acuity preservation in indeterminate lesions/small choroidal melanoma. Mechanism (light-activated viral-like particle) is validated. Phase 3 uses sham control against a disease with known natural progression, favoring separation. Risks: operational execution, endpoint at 65 weeks, and disclosure timing beyond primary completion (Nov 2027).-

Phase 3 CoMpass is SPA-agreed, fully enrolled (108 pts), sham-controlled with time-to-tumor-progression endpoint. Positive Phase 2 end-of-study data and mechanistically strong VDC with FDA Fast Track/Orphan support success odds above base rate. However, small trial size, sham control durability, and 15-month endpoint variability add risk. Topline not until 2H27, well past this market's window—resolution timing risk is significant.reasoning tilts moderately positive.:

Randomized, masked, sham-controlled Phase 3 design and an objective time-to-progression endpoint reduce bias. However, no prior efficacy data or sample size are provided, the mixed lesion population may dilute benefit, and drug-device-laser execution plus long follow-up add risk.

Randomized, masked, sham-controlled Phase 3 design and a clinically direct time-to-progression endpoint support interpretability. Active-not-recruiting status lowers enrollment risk. However, no effect-size, sample-size, or prior efficacy data are provided, and progression over 65 weeks can be sensitive to event rates and assessment consistency.

Phase 3 randomized, masked sham-controlled design supports a credible efficacy test, and the focused progression endpoint is clinically relevant. However, the mixed indeterminate-lesion/small-melanoma population, specialized injection/laser execution, and long follow-up create heterogeneity and operational risk. With no disclosed interim efficacy signal in the fields, the edge is modest.

Phase 3 masked RCT vs sham in small choroidal melanoma/IL; primary endpoint time-to-progression at 65 weeks; active not recruiting with 448 days to completion; strong design but no prior efficacy data in input and ocular microinjector delivery pose execution risk.

Phase 3 RCT, masked, sham-controlled for bel-sar vs control in IL/small CM. Primary endpoint: time-to-tumor progression (65 weeks). Active not recruiting, enrollment complete. Standard pivotal design with adequate power expected; no design/operational red flags in fields.

The Phase 3 CoMpass trial evaluating bel-sar vs. sham in early choroidal melanoma operates under an FDA SPA. Phase 2 data were highly de-risking, showing an 80% tumor control rate in Phase 3-eligible patients and halting tumor growth (from 0.351 mm/yr pre-treatment to 0.011 mm/yr). Given the sham control arm will reflect the natural history of steady progression, bel-sar's localized mechanism (light-activated targeted necrosis) has a very high probability of demonstrating a statistically significant improvement in time to tumor progression.

Phase 2 data demonstrated an 80% tumor control rate in Phase 3-eligible patients, with the tumor growth rate dropping from 0.351 mm/yr pre-treatment to 0.011 mm/yr post-treatment (p<0.0001). The Phase 3 CoMpass trial enriches for patients with documented tumor growth prior to enrollment and compares bel-sar to a sham control, making a positive time-to-progression result highly probable.

Phase 3 sham-controlled trial of novel light-activated therapy for small choroidal melanoma. Prior Phase 2 data encouraging but small; risk of sham arm performing better than expected and masking challenges. Time-to-progression endpoint is objective but progression determination may be influenced. Typical Phase 3 oncology success ~40-50%, so intrinsic odds slightly below 50%.

Bel-sar (AU-011) showed strong Phase 2 signals in indeterminate lesions and small choroidal melanoma, with high rates of tumor shrinkage and low progression. The time-to-progression endpoint against sham control is well-suited to demonstrate benefit given expected progression in untreated arm. Phase 3 risk remains, but mechanism and prior data support a positive outcome.

Bel-sar targets indeterminate lesions/small melanoma with a novel mechanism. Phase 2 data showed strong efficacy in preventing progression. The primary endpoint (time to progression) is objective. Active status suggests operational stability. Historical success in this niche supports a positive outcome, though Phase 3 risks remain.

Phase 3, randomized masked design with sham control is robust, but ocular melanoma trials historically show modest efficacy. No disclosed phase‑2 data and the time‑to‑progression endpoint is difficult to improve over observation, making the chance of a positive result slightly below 50%.

Phase 3 ocular melanoma trial with time-to-progression endpoint at 65 weeks. Bel-sar is a novel virus-like drug+device combo requiring precise suprachoroidal delivery. Prior Phase 2 showed activity but small sample (n=~20). Sham control is appropriate. Primary completion 454 days out means data immature. Current status 'Active Not Recruiting' suggests enrollment complete but no interim reads disclosed. Tumor progression endpoint in indeterminate lesions/small CM is challenging—natural history variable, sham arm may do well. No prior Phase 3 validation for this mechanism in this indication....

Phase 3 ocular melanoma trial with time-to-progression endpoint at 65 weeks. Bel-sar is a novel viral-like drug-device combo with promising Phase 2 data but limited long-term follow-up. Sham control in vision-threatening tumors creates ethical/operational execution risk and potential unmasking. Small tumor population and indeterminate lesion heterogeneity may dilute effect. 460 days to completion adds disclosure risk. Prior data supportive but not definitive; mechanism is innovative but unproven at scale.

Phase 3, masked, sham-controlled design is rigorous. Bel-sar Phase 2 (CoMpass) showed encouraging tumor control in small CM. Novel photoactivation mechanism is mechanistically sound but adds execution risk. Time-to-progression at 65w is meaningful but variable. Enrollment complete (Active Not Recruiting) reduces operational risk. Rare disease with clear unmet need. Historical Phase 3 oncology success ~50-55%; modest edge from prior data.

Bel-sar Phase 3 with rigorous sham-controlled design in small choroidal melanoma/indeterminate lesions. Encouraging Phase 2 tumor control data and FDA Breakthrough Designation support optimism, but Phase 3 transition risk, novel viral-nanoparticle laser-activated mechanism, and small Phase 2 cohorts (n<50) create meaningful uncertainty. Sham control may progress slower than historical controls, making bar higher. Active not recruiting status suggests clean enrollment. Overall slightly below coin-flip given execution risks in rare ocular oncology.